CN117355301A - 处置剂 - Google Patents

处置剂 Download PDF

Info

Publication number
CN117355301A
CN117355301A CN202280036277.2A CN202280036277A CN117355301A CN 117355301 A CN117355301 A CN 117355301A CN 202280036277 A CN202280036277 A CN 202280036277A CN 117355301 A CN117355301 A CN 117355301A
Authority
CN
China
Prior art keywords
treatment agent
liposome
topotecan
surface area
aqueous phase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280036277.2A
Other languages
English (en)
Chinese (zh)
Inventor
下山晋
森干永
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fujifilm Corp
Original Assignee
Fujifilm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujifilm Corp filed Critical Fujifilm Corp
Publication of CN117355301A publication Critical patent/CN117355301A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280036277.2A 2021-05-24 2022-05-23 处置剂 Pending CN117355301A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163192329P 2021-05-24 2021-05-24
US63/192,329 2021-05-24
PCT/JP2022/021106 WO2022250015A1 (ja) 2021-05-24 2022-05-23 処置剤

Publications (1)

Publication Number Publication Date
CN117355301A true CN117355301A (zh) 2024-01-05

Family

ID=84228811

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280036277.2A Pending CN117355301A (zh) 2021-05-24 2022-05-23 处置剂

Country Status (6)

Country Link
US (1) US20240099974A1 (https=)
EP (1) EP4349338A4 (https=)
JP (1) JPWO2022250015A1 (https=)
CN (1) CN117355301A (https=)
TW (1) TW202313032A (https=)
WO (1) WO2022250015A1 (https=)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010518140A (ja) * 2007-02-14 2010-05-27 グラクソ グループ リミテッド Ｉｇｆ−１ｒに対する新規抗体
US20200016079A1 (en) * 2017-03-31 2020-01-16 Fujifilm Corporation Liposome composition and pharmaceutical composition
CN112789032A (zh) * 2018-10-01 2021-05-11 富士胶片株式会社 包含内含药物的脂质体组合物及铂制剂的组合医药

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100679906B1 (ko) 1998-09-16 2007-02-07 알자 코포레이션 리포솜-엔트랩된 토포이소머라제 억제제
JP2004501955A (ja) 2000-06-30 2004-01-22 アイネックス　ファーマシューティカルズ　コーポレイション リポソーム抗新生物薬剤およびその使用
EP1750673B1 (en) 2004-05-17 2009-12-02 Tekmira Pharmaceuticals Corporation Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof
US20090285878A1 (en) 2004-11-05 2009-11-19 Tekmira Pharmaceuticals Corporation Compositions and methods for stabilizing liposomal drug formulations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010518140A (ja) * 2007-02-14 2010-05-27 グラクソ グループ リミテッド Ｉｇｆ−１ｒに対する新規抗体
US20200016079A1 (en) * 2017-03-31 2020-01-16 Fujifilm Corporation Liposome composition and pharmaceutical composition
CN112789032A (zh) * 2018-10-01 2021-05-11 富士胶片株式会社 包含内含药物的脂质体组合物及铂制剂的组合医药

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DRESANG LR ET AL.: "Response of Merkel cell polyomavirus-positive merkel cell carcinoma xenografts to a survivin inhibitor", 《PLOS ONE》, vol. 8, no. 11, 18 November 2013 (2013-11-18), pages 1 - 14 *

Also Published As

Publication number Publication date
US20240099974A1 (en) 2024-03-28
WO2022250015A1 (ja) 2022-12-01
EP4349338A4 (en) 2024-09-04
JPWO2022250015A1 (https=) 2022-12-01
EP4349338A1 (en) 2024-04-10
TW202313032A (zh) 2023-04-01

Similar Documents

Publication Publication Date Title
KR20090023548A (ko) 암 치료
CN108136217B (zh) 用于治疗膀胱癌的制剂
JP2006248978A (ja) 新規なリポソーム製剤
US12370214B2 (en) Combined pharmaceutical formulation comprising drug-containing liposome composition and platinum preparation
US20150328234A1 (en) Bufalin liposome, preparation method therefor and application thereof
Liu et al. Ultrasound-triggered drug-loaded nanobubbles for enhanced T cell recruitment in cancer chemoimmunotherapy
EP4378453A1 (en) Dual-targeting biomimetic liposome containing elemene and cabazitaxel, and preparation method therefor and use thereof
JP4638500B2 (ja) 治療剤を封入するためのリポソームからなる組成物及び治療剤のリポソーム内での保持性を高めるための方法
WO2015172712A1 (zh) 维生素c与抗肿瘤药物协同作用的注射用药物组合物
US20240099975A1 (en) Anti-tumor agent
CN117355301A (zh) 处置剂
HK40101862A (zh) 处置剂
US20250064777A1 (en) Pharmaceutical composition for treatment of castration-resistant prostate cancer comprising bruceantin and nanoparticles
HK40102143A (zh) 抗肿瘤剂
US20250268827A1 (en) Combined medicinal drug including liposome composition encompassing topotecan or salt thereof and dna damage repair inhibitor
AU2021249949B2 (en) Antitumor agent
CA3173715C (en) Anti-tumor agent comprising a liposome encompassing gemcitabine, and uses thereof
KR102912021B1 (ko) 광민감제와 면역증강제를 포함하는 광면역 치료용 나노입자 및 이의 용도
CN102716085B (zh) 一种盐酸托泊替康脂质体注射剂
TW202203943A (zh) 抗腫瘤劑
HK40122907A (zh) 含有内含拓扑替康或其盐的脂质体组合物及dna损伤修复抑制剂的组合药物
CN118766959A (zh) 一种治疗乳腺癌的药物组合物及其应用
CN119258224A (zh) 熊果酸和多靶点酪氨酸激酶受体抑制剂的药物组合
Sabbatini S130 Friday 22 November Poster Sessions
OA17078A (en) New pediatric uses of cabazitaxel.

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40101862

Country of ref document: HK